MacDougall J, Davies M C, Overton C E, Gulekli B, Hall M, Bounds W, Jacobs H S, Guillebaud J G
Department of Reproductive Endocrinology, The Middlesex Hospital, London, UK.
Br J Fam Plann. 1999 Oct;25(3):96-100.
Prevention of osteoporosis is a major public health issue. Amenorrhoeic women have lower bone density than normally menstruating women, which is related to the duration of amenorrhoea and the severity of oestrogen deficiency. Bone mineral density (BMD) in amenorrhoeic women can be improved by oestrogen replacement in the form of the combined oral contraceptive pill (COCP), so increased BMD might be an important non-contraceptive benefit of the COCP in menstruating women. Previous studies have been variably reported, but have used different methodologies for measurement of BMD. We measured BMD using the DEXA technique in long term COCP users and compared this with menstruating women who had never used the COCP. No differences in bone density were found, suggesting that the COCP does not improve bone mass in menstruating women who are adequately oestrogenised by their own ovaries.
骨质疏松症的预防是一个重大的公共卫生问题。闭经女性的骨密度低于正常月经的女性,这与闭经持续时间和雌激素缺乏的严重程度有关。闭经女性的骨矿物质密度(BMD)可通过复方口服避孕药(COCP)形式的雌激素替代来改善,因此骨密度增加可能是COCP对月经女性的一项重要非避孕益处。以往的研究报告结果不一,但使用了不同的骨密度测量方法。我们使用双能X线吸收法(DEXA)技术测量了长期使用COCP者的骨密度,并将其与从未使用过COCP的月经女性进行比较。未发现骨密度有差异,这表明COCP不会改善自身卵巢雌激素充足的月经女性的骨量。